Arbutus Biopharma Corp
ABUS4.420USD
-0.010-0.23%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
847.06MMarket Cap
LossP/E TTM
More Details of Arbutus Biopharma Corp Company
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.
Company Info
Ticker SymbolABUS
Company nameArbutus Biopharma Corp
IPO dateNov 13, 2010
CEOMs. Lindsay Androski, J.D.
Number of employees44
Security typeOrdinary Share
Fiscal year-endNov 13
Address701 Veterans Circle
CityWARMINSTER
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code18974
Phone16044193200
Websitehttps://www.arbutusbio.com/
Ticker SymbolABUS
IPO dateNov 13, 2010
CEOMs. Lindsay Androski, J.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Bishop
Mr. Joseph Bishop
Independent Director
Independent Director
--
--
Mr. Matthew Gline
Mr. Matthew Gline
Independent Director
Independent Director
--
--
Mr. Robert Alan Beardsley
Mr. Robert Alan Beardsley
Independent Director
Independent Director
--
--
Ms. Lindsay Androski, J.D.
Ms. Lindsay Androski, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Roger Sawhney, M.D.
Dr. Roger Sawhney, M.D.
Independent Director
Independent Director
--
--
Mr. Tuan Nguyen
Mr. Tuan Nguyen
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Bishop
Mr. Joseph Bishop
Independent Director
Independent Director
--
--
Mr. Matthew Gline
Mr. Matthew Gline
Independent Director
Independent Director
--
--
Mr. Robert Alan Beardsley
Mr. Robert Alan Beardsley
Independent Director
Independent Director
--
--
Ms. Lindsay Androski, J.D.
Ms. Lindsay Androski, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Roger Sawhney, M.D.
Dr. Roger Sawhney, M.D.
Independent Director
Independent Director
--
--
Mr. Tuan Nguyen
Mr. Tuan Nguyen
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Roivant Sciences Ltd.
20.26%
Morgan Stanley Investment Management Inc. (US)
12.03%
Whitefort Capital Management, LP
6.96%
BlackRock Institutional Trust Company, N.A.
5.98%
Two Seas Capital LP
5.45%
Other
49.31%
Shareholders
Shareholders
Proportion
Roivant Sciences Ltd.
20.26%
Morgan Stanley Investment Management Inc. (US)
12.03%
Whitefort Capital Management, LP
6.96%
BlackRock Institutional Trust Company, N.A.
5.98%
Two Seas Capital LP
5.45%
Other
49.31%
Shareholder Types
Shareholders
Proportion
Hedge Fund
23.08%
Corporation
20.26%
Investment Advisor/Hedge Fund
20.18%
Investment Advisor
15.86%
Research Firm
3.02%
Individual Investor
1.63%
Bank and Trust
0.28%
Pension Fund
0.16%
Insurance Company
0.03%
Other
15.50%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
299
156.35M
81.56%
+5.22M
2025Q1
315
155.95M
81.43%
+5.02M
2024Q4
297
147.19M
78.79%
-1.77M
2024Q3
299
144.28M
77.46%
-1.67M
2024Q2
274
139.38M
74.89%
+5.03M
2024Q1
272
125.84M
69.82%
-6.90M
2023Q4
273
121.03M
71.96%
-8.47M
2023Q3
278
113.50M
68.12%
-7.67M
2023Q2
283
108.80M
65.65%
-8.52M
2023Q1
288
105.13M
63.70%
-2.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Roivant Sciences Ltd.
38.85M
20.28%
--
--
Feb 25, 2025
Morgan Stanley Investment Management Inc. (US)
22.70M
11.85%
+1.47M
+6.92%
Mar 31, 2025
Whitefort Capital Management, LP
13.31M
6.95%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
11.41M
5.96%
-258.87K
-2.22%
Mar 31, 2025
Two Seas Capital LP
9.47M
4.94%
+725.00K
+8.29%
Mar 31, 2025
The Vanguard Group, Inc.
8.92M
4.66%
-27.04K
-0.30%
Mar 31, 2025
State Street Global Advisors (US)
4.36M
2.28%
-663.12K
-13.19%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.54M
1.85%
+59.01K
+1.69%
Mar 31, 2025
Goldman Sachs & Company, Inc.
2.03M
1.06%
+1.53M
+305.88%
Mar 31, 2025
Adar1 Capital Management LLC
1.88M
0.98%
+324.31K
+20.86%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
